The financials
Summit Therapeutics Inc. by the numbers
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net income | −$216M | −$566M | n/a |
| Diluted EPS | −$0.28 | −$0.76 | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2023Total $0.00
License And Service grew -100% year on year
Segment Latestyear on year
- License And Service$0.00$0.00year on year -100%-100%